Estimating the Uncertainty of Structured Pharmaceutical Development and Manufacturing Process Execution Risks Using a Prospective Causal Risk Model (PCRM)

The microelectronics industry is heavily tasked with minimizing contaminates at all steps of the manufacturing process. Particles are generated by physical and/or chemical fragmentation from a mothersource. The tools and macrovolumes of chemicals used for processing, the environment surrounding the process, and the circuits themselves are all potential particle sources. A first step in eliminating these contaminants is to identify their source. Elemental analysis of the particles often proves useful toward this goal, and energy dispersive spectroscopy (EDS) is a commonly used technique. However, the large variety of source materials and process induced changes in the particles often make it difficult to discern if the particles are from a common source.Ordination is commonly used in ecology to understand community relationships. This technique usespair-wise measures of similarity. Separation of the data set is based on discrimination functions. Theend product is a spatial representation of the data with the distance between points equaling the degree of dissimilarity.

Download Full-text

244 Derivation and validation of a clinical risk-model in heart failure based on 6-min walk test performance and NT-proBNP status

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(07)60125-8 ◽

2007 ◽

Vol 6 (1) ◽

pp. 46-46

Author(s):

L FRANKENSTEIN ◽

L INGLE ◽

A REMPPIS ◽

D SCHELLBERG ◽

C SIGG ◽

...

Keyword(s):

Heart Failure ◽

Test Performance ◽

Risk Model ◽

Walk Test ◽

Clinical Risk

Download Full-text

Water in the Vinegar Manufacturing Process

Industrial & Engineering Chemistry ◽

10.1021/ie50507a639 ◽

1952 ◽

Vol 44 (3) ◽

pp. 449-449

Author(s):

Rudolph Allgeier ◽

Reuben Wisthoff ◽

Frank Hildebrandt

Keyword(s):

Manufacturing Process

Download Full-text

A Perspective on Low Molecular Weight Heparins in the Management of Thrombosis

Hämostaseologie ◽

10.1055/s-0038-1655237 ◽

1993 ◽

Vol 13 (S 01) ◽

pp. S5-S11 ◽

Cited By ~ 4

Author(s):

Debra Hoppensteadt ◽

Jeanine Walenga ◽

A Ahsan ◽

O Iqbal ◽

W Jeske ◽

...

Keyword(s):

Molecular Weight ◽

Mechanism Of Action ◽

Manufacturing Process ◽

Laboratory Tests ◽

Low Molecular Weight ◽

Low Molecular Weight Heparins ◽

Pharmacological Management

SummaryThe introduction of low molecular weight heparins has added a new dimension to the pharmacological management of thrombotic disorders. Because of different chemical and pharmacological characteristics, due to the manufacturing process, each LMWH should be considered as a distinct entitity and only be used for its given indication. A list of commercially available LMWHs is included. The mechanism of action of the LMWHs and their use in various disorders are discussed. Available laboratory tests for monitoring LMWHs are presented and their limitations pointed out.

Download Full-text